Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 15, 2022 - Issue
Submit an article Journal homepage
162
Views
5
CrossRef citations to date
0
Altmetric
CASE SERIES

Successful Treatment of Non-Langerhans Cell Histiocytosis With Topical Rapamycin in Two Pediatric Cases

Raden Mohamad Rendy Ariezal EffendiDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, IndonesiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4471-0568
ORCID Icon,
Trustia RizqandaruDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, IndonesiaORCID Iconhttps://orcid.org/0000-0002-0622-7797
ORCID Icon,
Renata YuliasariDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, IndonesiaORCID Iconhttps://orcid.org/0000-0003-4943-0864
ORCID Icon,
Srie Prihianti GondokaryonoDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, IndonesiaORCID Iconhttps://orcid.org/0000-0003-2327-2773
ORCID Icon,
Inne Arline DianaDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, IndonesiaORCID Iconhttps://orcid.org/0000-0002-9409-5148
ORCID Icon &
Reiva Farah DwiyanaDepartment of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran - Dr. Hasan Sadikin Hospital, Bandung, IndonesiaORCID Iconhttps://orcid.org/0000-0001-9350-0239
ORCID Icon
Pages 1575-1582 | Received 30 May 2022, Accepted 28 Jul 2022, Published online: 06 Aug 2022

References

  • Schmieder A, Goerdt S, Utikal J, et al. Histiocytosis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, editors. Fitzpatrick’s Dermatology. 1, 9th. New York: Mc Graw Hill; 2019:2018–2041.
  • Ratzinger G, Zelger BWH. Juvenile Xanthogranuloma and Other Non-Langerhans Cell Histiocytoses. In: Hoeger P, Kinsler V, Yan A, editors. Harper’s Textbook of Pediatric Dermatology. Juvenile Xanthogranuloma and Other Non-Langerhans Cell Histiocytoses. Pondicherry: Wiley-Blackwell; 2020:1078–1096.
  • Emile J-F, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood J Am Soc Hematol. 2016;127(22):2672–2681.
  • Polat Ekinci A, Buyukbabani N, Baykal C. Novel clinical observations on benign cephalic histiocytosis in a large series. Pediatr Dermatol. 2017;34(4):392–397. doi:10.1111/pde.13153
  • Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the Kiel pediatric tumor registry. Am J Surg Pathol. 2005;29(1):21–28. doi:10.1097/01.pas.0000147395.01229.06
  • Paller AS, Mancini AJ. Hurwitz Clinical Pediatric Dermatology. Elsevier; 2016.
  • Koca R, Bektaş S, Altinyazar HC, Sezer T. Benign cephalic histiocytosis: a case report. Ann Dermatol. 2011;23(4):508–511. doi:10.5021/ad.2011.23.4.508
  • Rapini R. Non-Infectious Granuloma. In: Rapini R, editor. Practical Dermathopathology. Houston: Sanders; 2014. 115–116.
  • Patterson JW. Cutaneous infiltrates-nonlymphoid. In: Patterson JW, editor. Weedon’s Skin Pathology. Dallas: Churcill Livingstone; 2016:1149–1151.
  • Elder DE, Elenitsas R, Johnson B, Loffreda M, Miller J, Miller OF. Histopathology of the skin. In: Elder DE, Elenitsas R, Johnson B, Loffreda M, Miller J, Miller OF, editors. Histopathology of the skin. Philadelphia: Lippincot William and Wilkin; 2007.
  • Wee LWY, Ling HY, Ho VPY, Foong AYW, Koh MJA. Juvenile xanthogranulomas in Asian children. Dermatol Ther. 2022;35(2):e15224. doi:10.1111/dth.15224
  • Park YW, Koh EJ, Choi HY. Rapid-growing juvenile xanthogranuloma on the scalp in 18-month-old girl. J Korean Neurosurg Soc. 2011;50(3):271. doi:10.3340/jkns.2011.50.3.271
  • Habeshian K, Silverman RA, DeKlotz CM. Treatment of benign cephalic histiocytosis with topical 1% rapamycin ointment. Pediatr Dermatol. 2019;36(3):411–413. doi:10.1111/pde.13800
  • Haemel AK, O’Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146(7):715–718. doi:10.1001/archdermatol.2010.125
  • Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003;27(5):579–593. doi:10.1097/00000478-200305000-00003
  • Jih DM, Salcedo SL, Jaworsky C. Benign cephalic histiocytosis: a case report and review. J Am Acad Dermatol. 2002;47(6):908–913. doi:10.1067/mjd.2002.124602
  • Micali G, Verzl AE, Tedeschi A, Lacarruba F. Juvenile xanthogranuloma. In: Micali G, Lacarruba F, Stinco G, Argenziani G, Neri I, editors. Atlas Pediatric Dermatoscopy. Gewerbestrasse: Springer; 2018:205–212.
  • Bañuls J, Arribas P, Berbegal L, DeLeón F, Francés L, Zaballos P. Yellow and Orange in cutaneous lesions: clinical and dermoscopic data. J Eur Acad Dermatology Venereol. 2015;29(12):2317–2325. doi:10.1111/jdv.13249
  • Oza VS, Stringer T, Campbell C, et al. Congenital‐type juvenile xanthogranuloma: a case series and literature review. Pediatr Dermatol. 2018;35(5):582–587. doi:10.1111/pde.13544
  • Madke B. Topical rapamycin (sirolimus) for facial angiofibromas. Indian Dermatol Online J. 2013;4(1):54. doi:10.4103/2229-5178.105488
  • Mutizwa M, Berk D, Anadkat M. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1 mg mL− 1) in two patients with tuberous sclerosis. Br J Dermatol. 2011;4(165):922–923. doi:10.1111/j.1365-2133.2011.10476.x
  • Vasani R. Topical sirolimus in the treatment of facial angiofibromas. Indian J Drugs Dermatol. 2018;4(2):49. doi:10.4103/ijdd.ijdd_34_18
  • Gianfreda D, Nicastro M, Galetti M, et al. Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood J Am Soc Hematol. 2015;126(10):1163–1171.
  • Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: the TREATMENT randomized clinical trial. JAMA dermatol. 2018;154(7):773–780. doi:10.1001/jamadermatol.2018.0464

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.